XTL Biopharmaceuticals
XTLB
6 hedge funds and large institutions have $1.31M invested in XTL Biopharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 6 → 6 (0)
0% less ownership
Funds ownership: 0.02% → 0.02% (-0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
39% less capital invested
Capital invested by funds: $2.13M → $1.31M (-$828K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$3.46K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$526 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$56K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$9.49K |
| 3 |
Morgan Stanley
New York
|
-$2.08K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NC
1
Noked Capital
Tel Aviv,
Israel
| $551K | – | – | – |
|
|
NI
2
Noked Israel
Ramat Hasharon,
Israel
| $551K | – | – | – |
|
|
3
Morgan Stanley
New York
| $141K | -$2.08K | -150 | -1% |
|
|
4
Renaissance Technologies
New York
| $64K | +$3.46K | +250 | +4% |
|
|
5
Citadel Advisors
Miami,
Florida
| – | -$56K | -3,200 | Closed |
|
|
6
UBS Group
Zurich,
Switzerland
| – | -$9.49K | -686 | -95% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| – | +$526 | +38 | New |
|
XTLB Hedge Fund Activity: Q4 2021 in Review
6 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q4 2021, worth a combined $1.31M — down 39% from $2.13M a quarter earlier.
Fund positioning in XTLB was balanced in Q4 2021: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $3.46K. The largest seller was Citadel Advisors, exiting entirely with an estimated $56K sold.
- 6 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $1.31M of XTL Biopharmaceuticals stock for Q4 2021, down 39% quarter-over-quarter.
- 1 fund opened new XTL Biopharmaceuticals positions in Q4 2021 and 1 closed out, a net change of 0 holders.
- The largest XTL Biopharmaceuticals buyer in Q4 2021 was Renaissance Technologies, an estimated $3.46K added.
- The largest XTL Biopharmaceuticals seller in Q4 2021 was Citadel Advisors, an estimated $56K sold.
Based on aggregated 13F filings for Q4 2021.